Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis

EMERYVILLE, Calif., Jan. 19, 2024. Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced it received...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials